Exp Clin Endocrinol Diabetes
DOI: 10.1055/a-1235-5617
Commentary

COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?

Stella Papachristou
1  Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece
,
Theano Penlioglou
1  Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece
,
Anca Pantea Stoian
2  Diabetes, Nutrition and Metabolic Diseases Department, “Carol Davila” University of Medicine, Bucharest, Romania
,
Nikolaos Papanas
1  Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece
› Author Affiliations
Funding: No funding or sponsorship was received for this study or publication of this article.

Abstract

Novel coronavirus infectious disease (COVID-19) has been recognised as a pandemic by the World Health Organization (WHO) [1]. Mortality and morbidity are higher in elderly individuals and those with comorbidities, such as diabetes mellitus (DM), obesity, hypertension, respiratory tract diseases, coronary heart disease or cancer [1]. Indeed, two thirds of individuals who died from COVID-19 had DM in Italy [2].



Publication History

Received: 26 May 2020
Received: 02 August 2020

Accepted: 06 August 2020

Publication Date:
10 September 2020 (online)

© 2020. Thieme. All rights reserved.

© Georg Thieme Verlag KG
Stuttgart · New York